Hepatitis D Market to Grow with a CAGR of 5.25% through 2029

Increasing prevalence of Hepatitis D and growing awareness and screening programs are factors driving the Global Hepatitis D Market in the forecast period 2025-2029.

According to TechSci Research report, “Hepatitis D Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Hepatitis D Market stood at USD 1.11 Billion in 2023 and is anticipated to grow with a CAGR of 5.25% through 2029. Hepatitis D, caused by the hepatitis D virus (HDV), is a serious liver infection that occurs only in conjunction with hepatitis B virus (HBV) infection. While hepatitis B affects millions worldwide, hepatitis D, although less common, poses significant health risks to those affected. The global hepatitis D market is influenced by various factors, including advancements in healthcare, increasing awareness, prevalence of HBV infections, and the emergence of novel treatment options.

Hepatitis D can only infect individuals who are already infected with hepatitis B. As hepatitis B remains a significant global health concern, with millions of new infections each year, the prevalence of hepatitis D is also substantial. The rising incidence of hepatitis B infections, particularly in regions with poor healthcare infrastructure and limited access to preventive measures, serves as a major driver for the hepatitis D market.

Efforts to raise awareness about hepatitis D and the importance of screening programs have intensified in recent years. Public health initiatives, advocacy campaigns, and educational programs contribute to increased screening rates, leading to early detection and better management of the disease. The expansion of screening programs, especially in high-risk populations and endemic regions, drives the demand for diagnostic tests and treatment options, thereby stimulating market growth.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Hepatitis D Market”

The Global Hepatitis D Market is segmented into type, diagnosis and company.

Based on diagnosis, the elastography segment has emerged as the fastest growing segment in the  Global Hepatitis D Market. Elastography techniques offer a non-invasive way to assess liver fibrosis and stiffness, which are crucial indicators of liver health in patients with hepatitis D. Traditionally, liver biopsy was used to assess fibrosis, but this invasive procedure has limitations and risks. Elastography methods provide an alternative that is safer and more comfortable for patients. Elastography techniques have shown high accuracy and reliability in detecting liver fibrosis associated with hepatitis D. This includes methods like transient elastography (FibroScan), magnetic resonance elastography (MRE), and shear wave elastography (SWE). These techniques provide quantitative measurements of liver stiffness, aiding in disease staging and monitoring. In hepatitis D, assessing liver fibrosis is crucial for determining disease progression and guiding treatment decisions. Elastography allows for regular monitoring of liver stiffness over time without the need for repeated invasive procedures like liver biopsy. The increasing prevalence of hepatitis D globally has driven the demand for accurate and efficient diagnostic tools. Elastography methods fulfill this need by offering a reliable means of assessing liver fibrosis in hepatitis D patients. Healthcare systems worldwide are increasingly focused on adopting non-invasive diagnostic techniques. Elastography aligns with this trend by providing a comprehensive assessment of liver health in hepatitis D patients without the drawbacks associated with invasive methods.

Based on region, Asia Pacific is the fastest growing region  in the  Global Hepatitis D Market. Asia Pacific has a high burden of hepatitis D virus (HDV) infections, particularly in countries such as China, India, and Southeast Asian nations. The region accounts for a significant proportion of the global hepatitis D cases. Factors such as dense population, inadequate healthcare infrastructure in certain areas, and limited access to vaccination contribute to the high prevalence rates. Over recent years, there has been increasing awareness about hepatitis D in Asia Pacific, leading to more people getting screened for the virus. This increased detection of cases has contributed to a better understanding of the disease's prevalence and impact in the region. Many countries in the Asia Pacific region are investing in their healthcare infrastructure, including diagnostic facilities and treatment options for hepatitis D. This investment enhances the region's ability to diagnose and manage hepatitis D cases effectively. Pharmaceutical companies are increasingly focusing on developing treatments for hepatitis D. The availability of new and more effective therapies is driving market growth in the Asia Pacific region, where there is a significant unmet medical need. Governments and health organizations in the Asia Pacific region are implementing programs to combat viral hepatitis, including hepatitis D. These initiatives often involve vaccination campaigns, public awareness programs, and improved access to healthcare services, which collectively contribute to reducing the prevalence and impact of the disease.

Major companies operating in Global Hepatitis D Market are:

·         F. Hoffmann-La Roche Ltd

·         NanoGen Healthcare Pvt. Ltd.

·         PROBIOMED SA de CV

·         3SBio Group

·         Hepion Pharmaceuticals, Inc.

·         Antios Therapeutics, Inc.

·         PharmaEssentia Corporation

·         Replicor

·         Apotex Corp.

·         Mylan N.V

·         Aurobindo Pharma Limited

·         Gilead Sciences, Inc.

Download Free Sample Report

Customers can also request 10% free customization in this report

“The global hepatitis D market is driven by a combination of factors, including the prevalence of hepatitis B infections, growing awareness and screening programs, advancements in diagnostics, research and development of therapeutics, and regulatory initiatives. As efforts to combat hepatitis D intensify, stakeholders must collaborate to address unmet needs, expand access to care, and drive innovation in diagnosis and treatment. By leveraging these market drivers effectively, the healthcare community can make significant strides towards reducing the burden of hepatitis D and improving patient outcomes on a global scale”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Hepatitis D Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Acute, Chronic), By Diagnosis (Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Hepatitis D Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Hepatitis D Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com